In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Study investigates major cause of heart attacks in women

Stress, Psycho-Social and Cultural Aspects of Heart Disease
Risk Factors and Prevention

Munich, Germany – 25 Aug 2018: The initial findings of a study on spontaneous coronary artery dissection, a major cause of heart attacks in women, are reported today in a late breaking science session at ESC Congress 2018 (1).

Professor Jacqueline Saw, principal investigator, of the University of British Columbia, Vancouver, Canada, said: “Spontaneous coronary artery dissection (SCAD) causes around one-third of heart attacks in women under 60 years of age. SCAD was previously under-diagnosed and considered rare. Advances in intracoronary imaging techniques have improved diagnosis, yet we still know very little about the cause and natural history of SCAD.”

SCAD occurs when the lining of an artery supplying blood to the heart tears away from the artery’s outer layer. Blood leaks into the space between layers and forms a clot, which narrows the artery and restricts blood flow. Symptoms are similar to a heart attack and include chest pain, rapid heartbeat, pain in the arms, shoulders or jaw, and feeling sick, short of breath, sweaty, and light headed. If you have chest pains or other symptoms, call emergency immediately.

Treatment aims to restore blood flow to the heart. Some patients receive medication only, while others undergo a procedure to open the artery, either with a stent or by surgically bypassing the artery.

The Canadian SCAD Study examined the clinical presentation, natural history, treatment, and outcomes of SCAD. The researchers prospectively enrolled 750 patients presenting acutely with SCAD at 20 centres in Canada and two centres in the US between 2014 and 2018. Diagnosis of SCAD was adjudicated by an angiographic core laboratory. At the start of the study, information was collected on demographics, stressors and conditions that could have caused SCAD, and treatments. Patients are being followed for three years for major adverse cardiovascular events (MACE).

Today researchers report the baseline characteristics and outcomes in-hospital and at one month. The average age of patients in the study was 52 years and 89% were women.

Regarding possible causes for SCAD, about half of patients (49%) reported emotional stress prior to the event, and 30% reported physical stress (in 10% this was lifting more than 23 kg). The most common predisposing condition was fibromuscular dysplasia (40% of those assessed), which causes abnormal cell development in the arteries and can lead to narrowing (stenosis), aneurysms, or tears (dissections). Other predisposing conditions were five or more pregnancies (10%), being peripartum (5.3%), fertility treatment (5.1%), systemic inflammatory conditions (4.7%), and connective tissue disorders (3.5%).

Professor Saw said: “Emotional stress appears to be a major trigger for SCAD. Fibromusclar dysplasia, which is more common in women than men, also played a major role – it often has no symptoms but in some patients it causes headaches or a swooshing sound in the ears called pulsatile tinnitus.”

All patients presented with an acute coronary syndrome with their acute SCAD event, with 99.3% having a heart attack and 0.7% having unstable angina. The main symptom was chest pain, which occurred in nine out of ten patients. On angiography, the left anterior descending artery was most commonly affected (52%), and long diffuse narrowing was the most common feature (called type 2 SCAD; 58%).

The majority of patients were treated with medication only (85%), while 14% underwent percutaneous coronary intervention, and less than 1% had coronary bypass surgery.

Almost all patients (99.9%) survived to 30 days. The rate of MACE to 30 days was 7.5% (including recurrent heart attack in 5.1%, cardiac arrest in 3.3%, unplanned revascularisation in 2.1%, severe heart failure in 1.5%, mechanical haemodynamic support in 1.5%, stroke in 1.2%, heart transplant in 0.1%, and death in 0.1% of patients). Within 30 days after discharge, 5.1% had a repeat visit to the emergency room, and 2.5% were admitted for chest pain.

Professor Saw said: “Our study shows that SCAD primarily affects middle-aged women and most acute presentations occur at the same time as a heart attack. The vast majority of patients survived to 30 days with medication alone. However, recurrent heart attacks and emergency room visits were high within 30 days. More research is needed to determine the most appropriate treatment for patients with SCAD.”

ENDS

Notes to editor

SOURCES OF FUNDING: Canadian Institutes of Health Research.

DISCLOSURES: Dr. Saw has received unrestricted research grant supports (from the Canadian Institutes of Health Research, Heart & Stroke Foundation of Canada, National Institutes of Health, University of British Columbia Division of Cardiology, AstraZeneca, Abbott Vascular, St Jude Medical, Boston Scientific, and Servier), speaker honoraria (AstraZeneca, St Jude Medical, Boston Scientific, and Sunovion), consultancy and advisory board honoraria (AstraZeneca, St Jude Medical, and Abbott Vascular), and proctorship honoraria (St Jude Medical and Boston Scientific).

References 

(1) "Canadian SCAD Study – Canadian Spontaneous Coronary Artery Dissection Cohort Study” will be presented during the session Late Breaking Science in Interventional Cardiology 1 on Saturday 25 August from 11:00 to 12:30 on the Centre Stage – The Hub.

ESC Press Office
For press enquiries, independent comment, please contact the ESC Press Office at press@escardio.org

To access congress scientific resources visit ESC Congress 365.


About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

About ESC Congress 2018

ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2018 takes place 25 to 29 August at the Messe München in Munich, Germany. Explore the scientific programme.

 

This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2018. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.